Mylan, J&J In Authorized Generics Deal Over Ditropan XL

Law360, New York (December 20, 2005, 12:00 AM EST) -- Generic drug maker Mylan Laboratories and Johnson & Johnson subsidiary Alza have entered into an agreement over the rights to market a generic version of overactive bladder treatment Ditropan XL, adding more fuel to the fiery debate over authorized generics.

Under the agreement, Alza will supply Mylan with a generic form of Ditropan as soon as the patent litigation pending between the two companies over the drug is settled.

If another drug maker seeks to market Ditropan, Alza will begin supplying Mylan with the generic before...
To view the full article, register now.